Cigna Healthcare, the health benefits division of the Cigna Group, has released a set of digital tools aimed at improving the ...

Meanwhile, Atrium Health cancels many past medical debt judgments. Modern Healthcare: Cigna To Pull Back Medicare Advantage Plans In 8 States In 2025 Cigna Group's health insurance unit is scaling ...

Some Blue Cross and Blue Shield insurers dipped their toes into expanding coverage for blockbuster weight-loss drugs, then ...

Fifteen Connecticut companies made the 2025 Fortune 500 list of the largest U.S. corporations, which was announced Monday-- a sign of stability in the state's corporate sector. Bloomfield- ...

While employers aren’t yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among people with obesity. A new clinical trial has found that tirzepatide, sold ...

Cigna Group CI has outperformed the market over the past 15 years by 3.91% on an annualized basis producing an average annual return of 16.06%. Currently, Cigna Group has a market capitalization ...

Looking at the universe of stocks we cover at Dividend Channel, on 6/3/25, The Cigna Group (Symbol: CI), Macerich Co (Symbol: MAC), and Live Oak Bancshares Inc (Symbol: LOB) will all trade ex ...

Donation Options Search Search Search Boxes of the weight-loss medications Wegovy and Zepbound. JoNel Aleccia / AP Share Excess body weight can raise the risk of certain cancers. So researchers ...

Legacy Health patients with Cigna commercial insurance may lose in-network access to most Legacy facilities if the health system and insurer don’t reach a new agreement by June 30. At the heart ...

Over the past few years, demand for blockbuster medications like Ozempic, Wegovy and Zepbound skyrocketed. These drugs are typically prescribed to address a range of health issues, including ...

Credit: Getty Images With the FDA approval of Zepbound (tirzepatide) for obstructive sleep apnea, GLP-1 receptor agonists harbor potential beyond weight and diabetes management. In recent years ...